Ally Financial anticipates gains from Net Interest Margin (NIM) recovery amid a lower tax rate, while an impending CEO transition prompts adjustments to estimates, with Q4 earnings beating expectations but full-year guidance suggesting challenges in NIM, loan losses, and growth.
Genmab's legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth.
Tesla set to report Q4 earnings, investors focused on margin and demand outlook. Price cuts in 2023 helped demand, but can they continue? Wedbush maintains outperform rating and $350 PT. Short interest in stock has decreased. Uncertainty remains for EVs.